Clear Search

Showing 2 results for “Squire I”.

January 2023

Efficacy of Empagliflozin in Heart Failure with Preserved versus Mid-range Ejection Fraction: a Pre-specified Analysis of EMPEROR-Preserved

Nat Med. 2022;28:2512–2520 DOI: 10.1038/s41591-022-02041-5

Results from EMPEROR-Preserved demonstrated that empagliflozin improved CV death and HF hospitalisation – the primary outcome – in patients with HF and LVEF >40%. This pre-specified analysis of EMPEROR-Preserved aimed to evaluate the effect of empagliflozin in patients with HFpEF (LVEF ≥50%) compared with patients who had HFmrEF (LVEF 41–49%).

more…

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

N Engl J Med 2020;383:1413–24 DOI 10.1056/NEJMoa2022190

Empagliflozin demonstrated a reduction in CV death, HF hospitalisation, rate of eGFR decline and risk of serious renal outcomes in patients with chronic HF and reduced ejection fraction in the EMPEROR-reduced study.

more…